Investor.inva.com

  1. Home
  2. Investor.inva.com

Investor Relations

WEBA Phase 3 study of oral zoliflodacin met the primary endpoint when compared against the combination of injectable ceftriaxone and oral azithromycin, a current international …

Actived: 3 days ago

URL: https://investor.inva.com/news-releases/news-release-details/positive-results-announced-largest-pivotal-phase-3-trial-first

Investor Relations

WEBCore royalty platform on track; receiving GSK royalties of $61.9 million. Achieved net product revenues of $19.1 million, representing 66% year-over-year growth driven by …

Category:  Health Go Health

Investor Relations

WEBSulbactam-durlobactam is the first pathogen-targeted therapy under investigation for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial …

Category:  Health Go Health

Innoviva to Acquire La Jolla Pharmaceutical Company

WEBUnder the terms of the merger agreement, Innoviva, through a wholly owned subsidiary, will commence a tender offer on or before July 25, 2022 to acquire all of the outstanding …

Category:  Health Go Health

Investor Relations

WEBSingle-dose, oral zoliflodacin achieved 90.9% microbiological cure rate, demonstrating statistical non-inferiority compared to current global standard of care

Category:  Health Go Health

Investor Relations

WEBSUL-DUR is a targeted antibiotic that was specifically designed to treat serious infections caused by Acinetobacter baumannii, including multidrug-resistant and carbapenem …

Category:  Health Go Health

XACDURO®, The First and Only Antibiotic Developed to Target

WEBXACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can …

Category:  Health Go Health

Investor Relations

WEBIndicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter; First …

Category:  Health Go Health

Investor Relations

WEBPress Releases. Year. 2024. Date. Title. Other Formats. May 20, 2024. Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam …

Category:  Health Go Health

Investor Relations

WEBNew Drug Application (NDA) for sulbactam-durlobactam for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia …

Category:  Health Go Health

Investor Relations

WEBTrelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation in Europe for the Treatment of COPD

Category:  Health Go Health

Investor Relations

WEBTrelegy Ellipta met study primary endpoint demonstrating reduction in exacerbations compared with the dual therapies Anoro Ellipta and Relvar/Breo Ellipta in patients with …

Category:  Health Go Health

Investor Relations

WEBTrelegy Ellipta Once-Daily Single Inhaler Triple Therapy Receives Positive Opinion from the CHMP in Europe for Appropriate Patients with COPD

Category:  Health Go Health

Investor Relations

WEBBURLINGAME, Calif.--(BUSINESS WIRE)--May 8, 2024-- Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties …

Category:  Health Go Health

Investor Relations

WEBBURLINGAME, Calif.--(BUSINESS WIRE)--Mar. 13, 2023-- Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other …

Category:  Health Go Health

Investor Relations

WEBZai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated …

Category:  Health Go Health

Armata Pharmaceuticals Announces New Financing and …

WEBSigns new $25 million credit agreement and extension of existing secured convertible credit agreement. Appoints world‐renowned healthcare leader Dr. Deborah L. Birx as Chief …

Category:  Health Go Health

Investor Relations

WEBSafety Profile of Sulbactam-Durlobactam (SUL-DUR) Versus Colistin Therapy in Patients With Acinetobacter baumannii-calcoaceticus Complex (ABC) Infections from the Global, …

Category:  Health Go Health

Investor Relations

WEBDerek Small is founding Managing Director of Luson Bioventures, a mental health and neuroscience focused biopharmaceutical venture creation firm founded in 2007, and has …

Category:  Health Go Health

Investor Relations

WEBStay up to date on latest developments at Innoviva.

Category:  Health Go Health

Investor Relations

WEBLONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA-- (Marketwired) -- 05/24/16-- GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Innoviva, Inc. (NASDAQ: …

Category:  Health Go Health

Investor Relations

WEBMARINA DEL REY, Calif., Feb. 9, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company …

Category:  Health Go Health

Top Categories

 › Appendicitis

 › Headaches

 › Gout

 › Women's Health

 › Thyroid

 › Sleep

 › Skin

 › Sexual Health

 › Senior Health

 › Pregnancy

 › Oral Health

 › Neurology

 › Migraine

 › Mental Health

 › Men's Health

 › Menopause

 › Medications

 › Lung Conditions

 › Infectious Disease

 › HIV/AIDS

Popular Searched

 › Eat healthy be active

 › Cary nc health care providers

 › Rio hondo mental health clinic

 › Frontier home health canon city

 › Tina jones health history plan

 › Network health pharmacy list

 › United health care products order

 › Health symptom checker for man

 › Ihs contract health regulations

 › Best supplement to improve gut health

Recently Searched

 › Health experts in samoa

 › Custom health care solutions phone number

 › Smartcare zambia health system

 › Glenoaks advent health cafe

 › Healthy cooking crock pot recipes

 › Health and society minor course

 › Bc health insurance contact details

 › Health barn for kids

 › Reactive health charlottetown ny

 › Iu health pharmacy indiana